Last reviewed · How we verify

NCT05391633

Maternal Voice and Quantitative EEG (qEEG)

Terminated NA Last updated 15 September 2025
What this trial tests

NA trial testing Recorded Maternal Voice in Prematurity in 14 participants. Terminated before completion.

Timeline
15 February 2022
Primary endpoint
12 June 2024
12 June 2024

Quick facts

Lead sponsorUniversity of New Mexico
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment14
Start date15 February 2022
Primary completion12 June 2024
Estimated completion12 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of New Mexico

Who can join

Adults 28 Weeks to 33 Weeks, any sex, with Prematurity or Development Delay. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prematurity

Currently open trials in the same condition.

Other University of New Mexico trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05391633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing